Barclays’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-38,001
| Closed | -$357K | – | 5280 |
|
|
2020
Q3 | $357K | Buy |
38,001
+7,865
| +26% | +$74.8K | ﹤0.01% | 3475 |
|
|
2020
Q2 | $230K | Buy |
30,136
+396
| +1% | +$3.03K | ﹤0.01% | 3959 |
|
|
2020
Q1 | $185K | Sell |
29,740
-63,278
| -68% | -$557K | ﹤0.01% | 4370 |
|
|
2019
Q4 | $1.13M | Sell |
93,018
-985
| -1% | -$10.8K | ﹤0.01% | 3561 |
|
|
2019
Q3 | $1.09M | Sell |
94,003
-108,236
| -54% | -$1.14M | ﹤0.01% | 3586 |
|
|
2019
Q2 | $2.02M | Buy |
202,239
+155,104
| +329% | +$1.67M | ﹤0.01% | 2898 |
|
|
2019
Q1 | $607K | Sell |
47,135
-9,057
| -16% | -$135K | ﹤0.01% | 3934 |
|
|
2018
Q4 | $854K | Buy |
56,192
+1,133
| +2% | +$21.6K | ﹤0.01% | 3284 |
|
|
2018
Q3 | $1.1M | Buy |
55,059
+18,185
| +49% | +$414K | ﹤0.01% | 3526 |
|
|
2018
Q2 | $720K | Buy |
36,874
+8,158
| +28% | +$180K | ﹤0.01% | 3597 |
|
|
2018
Q1 | $578K | Buy |
28,716
+904
| +3% | +$15.3K | ﹤0.01% | 3831 |
|
|
2017
Q4 | $369K | Buy |
27,812
+22,280
| +403% | +$336K | ﹤0.01% | 4142 |
|
|
2017
Q3 | $103K | Sell |
5,532
-5,031
| -48% | -$93.8K | ﹤0.01% | 4925 |
|
|
2017
Q2 | $194K | Sell |
10,563
-7,397
| -41% | -$147K | ﹤0.01% | 4388 |
|
|
2017
Q1 | $404K | Sell |
17,960
-6,989
| -28% | -$167K | ﹤0.01% | 3617 |
|
|
2016
Q4 | $869K | Buy |
24,949
+16,243
| +187% | +$485K | ﹤0.01% | 2887 |
|
|
2016
Q3 | $213K | Buy |
8,706
+2,447
| +39% | +$61.2K | ﹤0.01% | 3921 |
|
|
2016
Q2 | $150K | Sell |
6,259
-29,420
| -82% | -$674K | ﹤0.01% | 4131 |
|
|
2016
Q1 | $820K | Buy |
35,679
+34,176
| +2,274% | +$811K | ﹤0.01% | 2701 |
|
|
2015
Q4 | $45K | Buy |
1,503
+897
| +148% | +$29K | ﹤0.01% | 4865 |
|
|
2015
Q3 | $23K | Sell |
606
-4,527
| -88% | -$281K | ﹤0.01% | 5400 |
|
|
2015
Q2 | $353K | Buy |
5,133
+2,131
| +71% | +$134K | ﹤0.01% | 3748 |
|
|
2015
Q1 | $162K | Sell |
3,002
-6,129
| -67% | -$292K | ﹤0.01% | 4503 |
|
|
2014
Q4 | $383K | Sell |
9,131
-76,349
| -89% | -$2.76M | ﹤0.01% | 4121 |
|
|
2014
Q3 | $2.65M | Sell |
85,480
-35,354
| -29% | -$754K | ﹤0.01% | 2403 |
|
|
2014
Q2 | $2.42M | Buy |
120,834
+37,928
| +46% | +$701K | ﹤0.01% | 2405 |
|
|
2014
Q1 | $1.58M | Buy |
82,906
+75,642
| +1,041% | +$1.61M | ﹤0.01% | 2785 |
|
|
2013
Q4 | $175K | Sell |
7,264
-2,677
| -27% | -$63K | ﹤0.01% | 5138 |
|
|
2013
Q3 | $209K | Buy |
9,941
+1,889
| +23% | +$44.6K | ﹤0.01% | 4996 |
|
|
2013
Q2 | $179K | Buy |
+8,052
| New | +$177K | ﹤0.01% | 5290 |
|
Barclays's AMAG Position: Q4 2020 in Review
Barclays sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 38,001 shares — an estimated $357K sold.
Barclays first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $2.65M in Q3 2014. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Barclays reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Barclays sold 38,001 AMAG Pharmaceuticals shares in Q4 2020, an estimated $357K.
- Barclays first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Barclays's AMAG Pharmaceuticals position peaked at $2.65M in Q3 2014.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.